Insulin aspart, recombinant Subcutaneous and Paclitaxel Concentrate Injection
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Paclitaxel Concentrate Injection and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: paclitaxel
Brand name: Onxol, Taxol
Synonyms: Paclitaxel, PACLitaxel (Conventional)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Paclitaxel Intravenous
- Insulin aspart, recombinant Subcutaneous-Paclitaxel Novaplus
- Insulin aspart, recombinant Subcutaneous-Paclitaxel protein-bound
- Insulin aspart, recombinant Subcutaneous-Paclitaxel protein-bound Intravenous
- Insulin aspart, recombinant Subcutaneous-Pacnex
- Insulin aspart, recombinant Subcutaneous-Pacnex LP
- Paclitaxel Concentrate Injection-Insulin degludec
- Paclitaxel Concentrate Injection-Insulin Degludec (U-100) Prefilled Pens
- Paclitaxel Concentrate Injection-Insulin Degludec (U-100) Vials
- Paclitaxel Concentrate Injection-Insulin Degludec (U-200) Prefilled Pens
- Paclitaxel Concentrate Injection-Insulin degludec and liraglutide
- Paclitaxel Concentrate Injection-Insulin degludec and liraglutide Subcutaneous